Literature DB >> 12220031

Prognosis following surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases.

Gina M Michels1, Deborah W Knapp, Dennis B DeNicola, Nita Glickman, Patty Bonney.   

Abstract

The purpose of this study was to determine if the presence of histopathologically tumor-free versus nontumor-free margins was prognostic for relapse or tumor-related death in dogs following surgical excision of single or multiple cutaneous mast cell tumors confined to the skin without evidence of metastasis to lymph nodes or other noncutaneous sites. Differences in tumor-related death or frequency of relapse between the two groups were not significant. Failure to achieve histopathological tumor-free margins frequently did not lead to local relapse. All tumor-related deaths occurred following local relapse. The lack of statistical support for an association between prognosis and histopathological tumor-free versus nontumor-free margins may be a result of small sample size.

Entities:  

Mesh:

Year:  2002        PMID: 12220031     DOI: 10.5326/0380458

Source DB:  PubMed          Journal:  J Am Anim Hosp Assoc        ISSN: 0587-2871            Impact factor:   1.023


  13 in total

1.  Factors influencing complete tumor excision of mast cell tumors and soft tissue sarcomas: a retrospective study in 100 dogs.

Authors:  Beatriz Monteiro; Sarah Boston; Gabrielle Monteith
Journal:  Can Vet J       Date:  2011-11       Impact factor: 1.008

2.  Multivariate survival analysis of histological parameters and clinical presentation in canine cutaneous mast cell tumours.

Authors:  R Preziosi; G Sarli; M Paltrinieri
Journal:  Vet Res Commun       Date:  2006-12-29       Impact factor: 2.459

3.  Predictive ability of fine-needle aspirate cytology for incompletely resected mast cell tumor surgical sites.

Authors:  Christopher E Lee; Stephanie S Lindley; Annette N Smith; Philippe Gaillard; Ralph A Henderson; Brad M Matz
Journal:  Can Vet J       Date:  2021-02       Impact factor: 1.008

4.  The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors.

Authors:  Joshua D Webster; Vilma Yuzbasiyan-Gurkan; John B Kaneene; RoseAnn Miller; James H Resau; Matti Kiupel
Journal:  Neoplasia       Date:  2006-02       Impact factor: 5.715

5.  Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.

Authors:  Giacomo Rossi; Chiara Bertani; Subeide Mari; Carlotta Marini; Giacomo Renzoni; Gregory Ogilvie; Gian Enrico Magi
Journal:  Vet Res Commun       Date:  2013-01-13       Impact factor: 2.459

6.  Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).

Authors:  A Lejeune; K Skorupski; S Frazier; I Vanhaezebrouck; R B Rebhun; C M Reilly; C O Rodriguez
Journal:  Vet Comp Oncol       Date:  2013-05-31       Impact factor: 2.613

7.  Evaluation of information presented within mast cell tumour histopathology reports in the United States: 2012-2015.

Authors:  Jennifer K Reagan; Laura E Selmic; Caroline Fallon; Elizabeth A Driskell; Laura D Garrett
Journal:  Vet Med Sci       Date:  2018-06-07

8.  Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs.

Authors:  Jaime A Olsen; Maurine Thomson; Kathleen O'Connell; Ken Wyatt
Journal:  Vet Med Sci       Date:  2018-05-24

Review 9.  Approaches to canine health surveillance.

Authors:  Dan G O'Neill; David B Church; Paul D McGreevy; Peter C Thomson; Dave C Brodbelt
Journal:  Canine Genet Epidemiol       Date:  2014-04-16

10.  Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.

Authors:  Pamela D Jones; Justine E Campbell; Graham Brown; Chad M Johannes; Paul Reddell
Journal:  J Vet Intern Med       Date:  2020-12-22       Impact factor: 3.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.